TriSalus Life Sciences, Inc.
News
Wolverine Asset Management LLC Takes $240,000 Position in TriSalus Life Sciences, Inc. (NASDAQ:TLSI)
Ticker Report Wolverine Asset Management LLC bought a new position in TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Free Report) in the second quarter, according to its most recent filing with the SEC. The firm...\n more…
TriSalus Life Sciences: A Strong Buy on Robust Revenue Growth and Promising Clinical Advancements
TipRanks Financial Blog Maxim Group analyst Jason McCarthy maintained a Buy rating on TriSalus Life Sciences (TLSI - Research Report) yesterday and set a price target of $...\n more…
TLSI Stock Earnings: TriSalus Life Sciences Beats EPS, Beats Revenue for Q2 2024
InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nTLSI stock results show that TriSalus Life Sciences beat analyst estimates for earnings per share and beat on revenue for the second...\n more…
TriSalus Reports Q2 2024 Financial Results and Business Update
Business Wire TriSalus Life Sciences Inc., (Nasdaq: TLSI), an oncology company integrating novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today...\n more…
Financial Comparison: TriSalus Life Sciences (NASDAQ:TLSI) and Nevro (NYSE:NVRO)
Ticker Report Nevro (NYSE:NVRO - Get Free Report) and TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two...\n more…
Financial Review: TriSalus Life Sciences (NASDAQ:TLSI) & ClearPoint Neuro (NASDAQ:CLPT)
Ticker Report ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) and TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare...\n more…